ABSTRACT
INTRODUCTION
Primary analysis of microarray data is currently mainly performed by different types of clustering algorithms (reviewed by Holloway et al., 2002; Quackenbush, 2002; Slonim, 2002) . These multivariate statistical analyses can be used to group genes and/or biological specimen into separate clusters based on similar gene expression patterns. Although clustering is very powerful for detecting relationships that exist among * To whom correspondence should be addressed. similar samples or genes, one major limitation is the difficulty of comparing different heterologous microarray databases. A clustering analysis of two types of cancer microarray databases is unlikely to reveal a potential overlap of differentially expressed genes. Since the expression pattern between the cancers is so different, also due to the different references used in the experiments, a small set of genes similarly altered in different data sets will not make any significant contribution to the clustering. Those genes will be scattered throughout the graph. Performing hierarchical clustering on merged databases will only discriminate the different sets before making subclusters within each set.
This limitation of standard clustering algorithms is also evident when grouping small sets of microarray experiments that do not share a common reference. In many instances, microarray experiments have been performed focussed on a single question or process in a particular cell system of interest. When addressing the question of whether genes identified by a specific treatment (such as a growth factor) in a certain cell type are also involved in a biological process (such as a comparison between arrested and growing cells) in another model system, standard clustering may prove an unsuitable method of detection. When different types of microarray platforms are involved in such a comparison, multivariate statistical clustering becomes even less informative.
To address the problems of identifying relevant subsets of genes in heterologous data sets, we have employed elaborate Venn diagram comparisons. A program was developed, Venn Mapper, to automatically compare overlap of differentially expressed genes in a multitude of microarray experiments and calculate the statistical significance (using z-values) of these overlaps. Microarrays can be clustered, based on similar z-value profiles, after which the genes responsible for the overlap can be further characterized by data and text mining. publications/2002/vantveer.htm) and prostate cancersamples (Dhanasekaran et al., 2001 , http://www.nature.com/ cgi-taf/DynaPage.taf?file=/nature / journal/ v412/ n6849/abs/ 412822a0_fs.html) were generated using different types of microarray platforms. The prostate cancer data set was generated using cDNA microarrays representing 9984 genes, while the breast cancer studies were performed using Agilent oligo microarrays harbouring 24 479 DNA oligonucleotides. Data from 117 breast cancer arrays and 53 prostate cancer arrays [data from Supplementary information, Figures 1C and 8 (Dhanasekaran et al., 2001) were downloaded and processed: ratios were log 2 transformed and every accession number provided, was linked to the Unigene Hs list (build no 146)]. For the breast cancer data set, only data of genes which were reliably measured according to the criteria as described (van't Veer et al., 2002) were used. With the Hs cluster number as unique identifier, we analysed 3472 genes present in both data sets in the Venn Mapper program.
For supervised analyses, the categories described by the authors were used (van't Veer et al., 2002; Dhanasekaran et al., 2001) . The breast cancer set was divided into oestrogen receptor (ER)-positive and negative groups, BRCA-mutated (BRCA) and wild type groups, and metastasis status (META) groups. This latter group consists of primary tumours of patients with a good (disease-free survival of at least 5 years) or poor prognosis (development of distant metastases within 5 years). The prostate set was subdivided in normal adjacent prostate (NAP), benign prostatic hyperplasia (BPH), localized prostate cancer (PCA), and metastatic prostate cancer (MET). All these categories were used to calculate averages of the gene ratios and were subsequently used as a supervised data set in the Venn Mapping program.
For the single array analysis, mRNA expression in stromal and epithelial cells was determined using the UniGEM V microarrays (Incyte Genomics Inc.). Human prostate stromal cells (hPrSC) and human prostate epithelial cells (hPrEC) were cultured according to the manufacturer's guidelines (Clonetics Corp., San Diego, CA). Poly(A) + RNA was extracted from these cells and RNA was reverse transcribed into Cy3-or Cy5-labelled first strand cDNA and hybridized to the UniGEM V microarray harbouring 7075 cDNA clones. Fluorescent intensities were scanned and data were analysed using GEMTools by Incyte Genomics Inc.
Venn Mapper
The Venn Mapper application is written in Perl. In short, the user is required to fill-in a fold ratio, which is used as a cutoff level for up-or down-regulation of a gene, i.e. the level of gene expression relative to the reference. Separate lists of up-and down-regulated genes are then established per array. Any combination of two lists (save the self-self situation) is compared for matching gene-identity (i.e. Hs number). The number of genes commonly affected in two experiments is determined (see Fig. 1 ). Using the Normal approximation to the binomial distribution, the following formulae are used to calculate whether this number of genes is statistically significant.
Let the number of genes regulated in one array divided by the total number of genes analysed be P exp in formula (1), n the number of regulated genes in another array, while r corresponds to the observed number of genes regulated in both arrays (see also Fig. 1 
Visualization and clustering
The z-value table generated by the Venn Mapper program was subjected to clustering and visualization using the Cluster and TreeView software (Eisen et al., 1998) . Clustering was performed using correlation centered, average linkage hierarchical clustering on both axes.
RESULTS

Venn Mapping
The main goal of Venn Mapping is to identify significant similarities between heterologous microarrays and identify the genes responsible for the resemblance. This unsupervised approach is based on a statistical evaluation of the number of co-occurring genes with expression levels different from the reference sample. A threshold for the fold difference is chosen primarily based on the quality of the measured ratios and the type of biological processes under study. We have investigated this approach on merged breast cancer and prostate cancer data sets using a two-fold gene expression difference threshold, as suggested by the authors (van't Veer et al., 2002; Dhanasekaran et al., 2001) .
Unsupervised clustering of z-values of gene co-occurrences
To evaluate whether Venn Mapping is comparable to standard hierarchical clustering, we performed Venn Mapping on the merged breast/prostate data set (see Supplementary information, Figure 1 ). In short, strongest correlations were seen between homologous arrays, e.g. ER-positive tumours are most similar with other ER-positive tumours, while ERnegative tumours show a weaker correlation with ER-positive tumours. Furthermore, genes up-regulated (i.e. increased level of gene expression relative to the reference) in ER-positive cancers are negatively correlated with genes down-regulated in other ER-positive cancers, grouping the breast tumours essentially similar to standard hierarchical expression ratio clustering (van't Veer et al., 2002) . The prostate samples are mainly grouped into the aforementioned categories (NAP, BPH, PCA and MET). The z-value profile classifies the prostate and breast tumours mainly in separate clusters although the subclusters alternate between experiments from prostate and breast origin. Most subclusters are primarily determined by the similarities found between arrays of either the prostateor breast cancer data set, so possible overlaps between the two data sets are still scattered throughout the graph. To clarify the similarities between the breast and prostate set, a table was generated with only the heterologous comparisons. A two-dimensional plot of z-value profiles was constructed with experiments from the prostate cancer set on the horizontal axis and the breast cancer data set on the vertical axis. The result after clustering the z-values is depicted in Figure 2 . It is clear that significant overlap between subsets of these cancers exists. For further investigation, we assigned two areas of interest, which include the predominant similarities. Area 2 is formed mainly by genes, which are down-regulated in metastatic prostate samples and down-regulated in BRCA mutated or metastatic breast cancers (i.e. breast cancers of patients who developed distant metastases within 5 years). By increasing the stringency of visibility in TreeView (z-value > 3.89, p < 0.0001) these similarities appear to be among the strongest correlations (data not shown). Even more notable, in area 1, experiments with genes down-regulated in breast samples and up-regulated in prostate samples are grouped. These will not be grouped in a standard hierarchical clustering procedure, but Venn Mapping makes it possible to group these arrays.
The two areas from Figure 2 were further analysed to determine whether these clusters carry relevant gene information, since it is possible that a similar z-value profile does not necessarily indicate identical genes being affected. The genes responsible for the overlap found between arrays in a given area were pooled and the frequency per gene was calculated (number of occurrences of a gene in the overlaps divided by the total number of overlaps within an area). This observed frequency of a gene within a cluster is only relevant if it is sufficiently deviant from the expected frequency. This expected frequency is the product of the frequencies of that gene being affected in the breast-and prostate data set. For each area, genes with more than a 10% occurrence and more than a factor-3 difference between observed and expected frequency were selected (see Supplementary information, Table 1 for gene lists). In Figure 3 , the relevant genes found in the two areas were used to depict the original expression ratio data from all the experiments. The vertical 'bars' clearly seen in both panels of Figure 3 are indicative of arrays in which the genes are similarly affected. These arrays (marked by blue blocks) appear to be the ones that are also found clustered in the areas depicted in Figure 2 . Thus, Venn Mapping is able to identify subsets of differentially expressed genes in arrays from heterologous data sets, otherwise masked in conventional clustering.
Supervised: consolidated representation
As described by van't Veer et al. (2002) , the breast cancer data set can be divided into ER-positive/negative tumours, BRCA mutated/wild type tumours, and primary tumours of patients who develop metastatic cancer within 5 years or remain disease-free for over 5 years (META). The study by Dhanasekaran et al. (2001) , shows clustering within four groups: NAP, BPH, PCA, and MET. In a supervised, summarized analysis the average of gene ratios across a category was calculated before Venn Mapping was performed. In addition, the possibility of making a comparison between single array data and a larger data set was investigated. Microrray data were included from a completely different source (UniGEM V microarray, see Systems and Methods) in which up-regulated genes indicate a higher expression in human prostate stromal cells as compared to human prostate epithelial cells.
Venn Mapping was performed on the averaged data set including the single stromal microarray experiment (Fig. 4) . The particular view of the averaged data appears easier to interpret. For example, genes up-regulated in ER-negative breast tumours (ER neg up) are also found up-regulated in BRCA mutated breast samples (BRCA pos up), which is as expected since virtually all BRCA mutated breast tumours in this study are ER negative. The breast/prostate comparisons in Figure 4 revealed two significant overlaps (Fig. 4, Fig. 3 . Two-dimensional TreeView plot of gene expression ratios. Each row represents a gene and each column a breast-or prostate sample as mentioned on top. The relevant genes found in the areas 1 and 2 from Figure 2 were used in the top and bottom panel, respectively. Blue boxes below each panel indicate the arrays found in the respective area of Figure 2 . Data is shown for 2-fold difference in expression; red means up-regulation, green down-regulation, black indicates less then 2-fold change, grey no data available. The genes of areas 1 and 2 are listed in Supplementary information, Table 1. arrows). One of these, the metastatic prostate down-regulated (Met down) with the BRCA mutated down-regulated (BRCA pos down), represents the subgroups mentioned in Figure 2 , area 2. The arrays overlapping in area 1 of Figure 2 were not represented in the averaged Venn Mapping analysis because the breast cancer samples within area 1 are dispersed throughout the above mentioned breast cancer categories. The single microarray data column (Stromal) shows a remarkable profile, where significant overlap (z-value >2.58, p < 0.01) is found between genes higher in stromal cells and lower in BRCA mutation positive breast tumours, and between stromal genes and metastatic prostate samples. Genes responsible for the overlaps found with the stromal comparisons are listed in Supplementary information, Table 1 .
DISCUSSION
Analyzing multiple microarrays on the basis of gene ratios is facilitated by the use of a standard reference. The absence of a general reference creates a huge problem in comparing heterologous microarray data sets. We have developed Venn Mapper to circumvent this problem on the basis of the number of commonly up-or down-regulated genes. Groups of arrays can be recognized, even if the direction of altered expression (up or down) of the genes responsible for the grouping does not coincide. This particular effect can be seen in Figure 2 , area 1 where arrays with genes down-regulated in breast cancer are grouped with arrays showing the same genes up-regulated in prostate samples. This can indeed be relevant, as up-and down-regulation of a gene is only informative with regard to the reference used in the experiment. The Venn Mapper program allows for all four possible variations of altered gene expression between two experiments and only correlates the identity of differentially regulated genes.
One potential problem associated with the use of fold-ratio difference is that the group of differentially expressed genes will also harbour false-positive genes. If these genes include common 'variable genes', the statistical analysis becomes biased. The quality of the microarrays, the number of times experiments were repeated, normalization, flagging and statistical evaluation (such as error model calculations) all play a role in eliminating these variable genes and therefore, determine the reliability of the microarray data and subsequent data evaluations, including Venn Mapper. One important aspect of Venn Mapping is the necessity to define the level for up-or down-regulation of a gene. The stringency of the cut-off level will affect the number of differentially expressed genes. We tested variations of the cut-off level on the data set used in Fig. 4 . Supervised plot: gene ratios were averaged across a category per breast or prostate data set (see Systems and Methods). Additionally, single array data was included and merged with the averaged data set. In this case, the total number of matching genes between the stromal and the breast cancer data sets and between the stromal and prostate data sets were evaluated separately. After Venn Mapping, the overlaps between the stromal array and the averaged sets are shown apart. Data is shown for p < 0.01 (z > 2.58). Black indicates p-value ≥ 0.01. In case an overlap was observed of exactly one gene, the z-value was not computed. Figure 2 and found that the number of statistical significant overlaps (p < 0.01) in this data set remained constant (about 14% of all overlaps) from a 1.3-to 3.5-fold-ratio difference (see Supplementary information, Figure 2 ). After randomization of this data set, less than 0.5% significant overlaps were observed when using a 2-fold-ratio cut-off. The Venn Mapper program offers the users the possibility to apply the threshold level most suited for the data set under study. It may be envisaged that for certain comparisons, different thresholds may be applied for the different data sets. An additional option is to use the mean centered gene ratios for the specific data set. In that case, up or down reflects the gene levels within that series of samples, independent of the reference. These variations in data treatment may result in different co-occurrences scores and overlap patterns, providing additional information. Both the unsupervised analysis (Figs 2 and 3 ) and the supervised analysis (Fig. 4) show that it is possible to extract biologically interesting data through Venn Mapping. A number of genes, that are down in BRCA-mutated breast samples are also found down in metastatic prostate samples. Another correlation can be seen between metastatic samples from both the breast and prostate cancers. Note here that metastatic breast samples refer to primary tumours of patients who developed distant metastases within 5 years, while the prostate samples being analysed are the metastatic tumours themselves. It is beyond the scope of this article to describe and evaluate the genes found in the overlaps mentioned above, but our analyses have identified genes found commonly regulated in subsets of both microarray databases. From the Venn Mapping comparisons, new biological hypotheses may be assessed. This can be illustrated by the analysis done in Figure 4 , wherein data from a single microarray was evaluated. In this array, gene expression levels from prostate stromal and epithelial cells were compared. The data on genes higher expressed in stromal cells were compared to the averaged data set using Venn Mapping. The principal correlation in the stromal/prostate comparisons is that genes indicative of the stroma were found down-regulated in metastatic prostate cancer. This agrees with the notion that distant metastatic prostate tumours have lost the prostate stromal environment, which is present in the normal prostate used as the reference probe. Stromal gene expression also correlated with the genes down-regulated in BRCA mutated tumours, which are also ER negative. Although not much is known about the correlation between stromal genes and the BRCA and/or ER pathways, it has been shown that the ER pathway plays an essential developmental role in the stromal compartment of hormone-sensitive tissues (Bigsby, 2002; Cunha et al., 2000; Russo et al., 2001) . Using the Venn Mapper program, genes have now been identified tentatively linking the stromal compartment to the BRCA or ER pathways.
We have shown that through Venn Mapping it is possible to compare microarray experiments from different platforms and with different reference probes. The Venn Mapper program can identify overlaps between heterologous samples without preliminary information (i.e. unsupervised) and extract the subset of genes responsible for the overlap. Following this filtering procedure, more detailed evaluation of the genes and the tumour characteristics may provide novel insights in the biological processes. In case there is knowledge on tumour type or subgroups (including grouping of samples after hierarchical clustering), supervised Venn Mapping can be performed on subgroup averages (Fig. 4) . This simplifies data interpretation and will also identify overlapping genes between averaged groups. Besides large data sets, comparisons of a few single microarray experiments can be performed by Venn Mapper. Moreover, all of these types of procedures (unsupervised, averaged supervised, and single arrays) are easily combined. Furthermore, Venn Mapping is not restricted to analysing tumour based data alone; it may be very informative combining microarray data studying apoptosis, hypoxia etc. with microarray data focussing on clinical backgrounds, like cancer, (viral) infections or neurological disorders.
